Horizon Discovery plcの資本の返還
Horizon Discovery plcの資本の返還は何ですか。
Horizon Discovery Group plcの資本の返還は-10.32%です。
資本の返還の定義は何ですか。
株主資本利益率は、株主資本の簿価との関係で事業の収益性の尺度です。これは、会計年度純利益を株主資本合計で除算することによって計算されます。
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
LSEのセクタHealth Careにおける資本の返還の企業と比べるHorizon Discovery plc
Horizon Discovery plcは何をしますか。
Horizon Discovery Group plc, a cell engineering company, engages in the design, manufacture, and application of gene editing and gene modulation tools in the United Kingdom, the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company operates through Screening, Research Reagents, Diagnostics, and BioProduction segments. It provides custom-made and off-the-shelf (OTS) RNAi gene modulation reagents, CRISPR reagents, synthetic SGRNAs, OTS cell models, and custom cell engineering services. The company also offers pooled CRISPR screens; arrayed RNAi and CRISPR screens, drug screens, and immunology assays; and RNAi and CRISPR screening libraries; and human T-Cell CRISPR screening service to meet the requirements of immunology based research in drug discovery. In addition, it provides OTS gene-edited CHO cells and custom CHO cell lines, and custom CHO gene engineering services; and OTS cell-based reference standards, made to order reference standards, and custom cell-based reference standards to evaluate molecular assays on a research use basis. The company serves customers in academic research labs, biopharmaceutical and diagnostics companies, and contract research and manufacturing organizations. It sells its products through direct field sales channel and e-commerce platform. The company has a partnership with the Rutgers, The State University of New Jersey to develop and commercialize base editing, a gene editing technology; strategic collaboration with Mammoth Biosciences to develop CRISPR tools to provide engineered cell lines for the biopharmaceutical industry; and collaboration with St George's University Hospital, London, and the European Molecular Genetics Quality Network to develop reference material for non-invasive prenatal testing. Horizon Discovery Group plc was founded in 2007 and is headquartered in Cambridge, the United Kingdom.
Horizon Discovery plcと類似の資本の返還
- Search Mineralsの資本の返還は-10.34%です。
- Blende Silver Corpの資本の返還は-10.34%です。
- Phenom Resourcesの資本の返還は-10.33%です。
- Perfectech Internationalの資本の返還は-10.33%です。
- Five9 Dl ,01の資本の返還は-10.32%です。
- NuCoal Resourcesの資本の返還は-10.32%です。
- Horizon Discovery plcの資本の返還は-10.32%です。
- Lanzhou Zhuangyuan Pasture Coの資本の返還は-10.32%です。
- Five9 Incの資本の返還は-10.32%です。
- StoneCoの資本の返還は-10.31%です。
- Daisho Microlineの資本の返還は-10.30%です。
- Finatis Societe Anonymeの資本の返還は-10.29%です。
- Victory Metalsの資本の返還は-10.29%です。